ArticleFrontiers in medicine2025
C-peptide and epicardial adipose tissue in dialysis-dependent chronic kidney disease patients.
Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Several studies suggest that C-peptide (CP) is involved in regulating lipolysis, adipokine release, and other functions in the adipose tissue. On the other hand, organ-specific adipose tissues, such as the epicardial adipose tissue (EAT), have been reported as an independent cardiovascular risk factor in patients on dialysis. This study aimed to evaluate the association between CP, EAT volume, and coronary artery calcification (CAC) as markers of cardiovascular risk, on subjects with type 2 diabetes receiving insulin and dialysis. Methods: This is a retrospective study on 62 patients with chronic kidney disease (CKD) stage 5 on dialysis awaiting kidney transplantation and referred for cardiovascular risk stratification at the Emory University Hospital. Computed tomography (CT) was used to assess CAC and to measure EAT volume. Demographic and anthropometric data were collected from all patients through record review. Results: The mean patient age was 43 ± 11 and 55% were women. None of the serum analytical parameters correlated with CP. Subjects with higher BMI exhibited higher levels of CP. EAT volume strongly correlated with CP levels, and it was significantly correlated with CAC. On the contrary, no correlation was found between CP and CAC. Conclusion: The significant association between EAT volume and CP suggests a potential role of CP in the cardiovascular physiopathology of patients with ESKD on dialysis. Insufficient statistical power was probably the cause of the lack of association of CP with CAC. Observational prospective studies are required to characterize CP as a cardiovascular risk marker in patients with ESKD.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.